A trial to explore the effect of PICSI on miscarriage rates
Research type
Research Study
Full title
A Randomised Controlled Trial to Explore the Effect of Physiological Intracytoplasmic Sperm Injection (PICSI) on Miscarriage Rates in Assisted Conception
IRAS ID
313487
Contact name
Jason Kasraie
Contact email
Sponsor organisation
The Shrewsbury and Telford Hospitals NHS Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 9 months, 1 days
Research summary
Physiological intracytoplasmic sperm injection (PICSI) is a technique used to select healthy, mature sperm for use in infertility treatment based on their physiological ability to bind to hyaluronan (HA), a natural compound found in the body. The relationship between sperm and hyaluronan can be used a marker of sperm maturity and optimal fertilising potential; this principle can be observed in vitro using a PICSI sperm selection device. The PICSI Dish contains microdots of hyaluronan, which only mature sperm bind to and these are selected by the embryologist prior to use in the intracytoplasmic sperm injection (ICSI) procedure.
Recurrent miscarriages following infertility treatment are mainly idiopathic, but can be linked with increased chromosomal abnormalities. PICSI has been shown to result in better embryo development and reduced chromosomal abnormalities, due to selection of mature sperm with low DNA damage. Therefore, PICSI may be a useful tool for reducing the rate of miscarriage following infertility treatment.
The recent HABSelect study investigated treatment outcomes following PICSI, and whilst they concluded no effect on livebirth rate, they found a significant association in their secondary analysis between PICSI and reduced miscarriage rate compared to ICSI (Miller, et al., 2019). The implications of the HABSelect study deserve to be explored further with miscarriage rate assessed as a primary outcome measure.
This proof-of-concept randomised-controlled-trial aims to investigate whether PICSI shows some promise that would merit evaluation in a fully-powered trial to assess its efficacy as an advanced sperm selection method for the reduction of miscarriage rate. Eligible study participants will be patients undergoing fertility treatment using ICSI, who have provided consent for PICSI. Patients will be randomly allocated to two groups: the control group will receive ICSI according to standard protocol, and the intervention group will have additional sperm selection by HA-binding in a PICSI dish.
REC name
London - Bromley Research Ethics Committee
REC reference
22/LO/0847
Date of REC Opinion
16 Dec 2022
REC opinion
Further Information Favourable Opinion